Eye Drop Application Monitor, Pilot Study

Glaucoma Clinical Trial

Official title:

A Novel Eye Drop Application Monitor to Assess Patient Compliance With a Prescribed Regimen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02639845
• Other study ID #: EDIT Phase I
• Status: Recruiting
• Phase: N/A
• First received: December 18, 2015
• Last updated: December 24, 2015
• Start date: November 2013
• Est. completion date: June 2017

Study information

• Verified date: December 2015
• Source: Retina Health Center
• Contact: Soratree Charoenthongtrakul, Ph.D.
• Phone: 239-337-3337
• Email: soratree[@]retinahealthcenter.com
• Is FDA regulated: No
• Health authority: United States: Lee Memorial Health System IRC
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if an eye drop video monitoring device can accurately assess (as compared to a patient's own log or a proprietary software) the exact amount and time of eye drop delivery to a patient's eye. It is our belief that the experimental device will help patients to be more compliant by: 1) providing a viewable format so patients can see what is happening when they are applying their drops 2) providing greater accuracy to doctors regarding when and how much medication was used 3) providing greater accuracy to doctors and patients regarding how much medication was actually delivered to a patients eye.

Description:

Subjects who agree to participate in this study will sign the informed consent form prior to the initiation of any research related procedures. Subjects will be consented by a study coordinator, their physician, or one of the physicians' staff with a strong knowledge of the purpose and design of the clinical trial. There will be two phases to this study: one phase will take place in the clinic, the other will take place at the subjects home. Each subject will participate in each phase. The at home phase will have two arms: one where the subjects are in phase 2 for 1 week, and one where they are in phase 2 for 4 weeks. It is initially anticipated that the 1 week arm will be enrolled first. As the results of the phase 1 come in and patients and physicians get an idea of the ease of using the system, phase 2 will be enrolled. Consented patients who were prescribed an eye drop medication regimen consisting of 1-5 different eye drop medications daily will be asked to participate in this study. Consent and technician assessment will be done by the subject's normal clinician or their designated clinical technician/trial coordinator, all of whom will have been certified for human clinical trials by the Lee Memorial Health System.

The first phase will take place under the controlled clinic environment, where we will assess the ability of the device and reading center to accurately determine the number and volume of drops that get into the eye and the time at which they are instilled as well as log them in an easy to use directory. Five hundred patients, and their designated caregiver if they are unable to apply the drops themselves, will be equipped with the EDAM, trained to use the device, and asked to dispense 10 drops of saline into their eye while in the clinic and being observed by a trained ophthalmic technician. During the application procedure, patients or their designated caregiver, and the observing clinical technician will be asked to write down how many drops were dispensed and if the drop landed in the eye, outside the eye, or half in and half out. All EDAM devices will be returned to the reading center at the Retina Health Center following each use or at the end of each day, along with the subject and technician questionnaires for further assessment. All data will be removed and cleared from the device by the reading center and stored on their secure servers. EDAMs will then be returned to the clinic where they came from for use on other subjects. Accuracy of the written logs (both patients/caregivers and technicians) will be compared to logs created by a technician at the reading center after viewing the application procedure in slow motion and to the read-outs from the drop assessment software.

For the second phase of the trial, these same 500 patients (and their designated caregivers) will be asked to use the EDAM at home for all drop applications for 7 or 28 consecutive days (50 in each group). Patients will be assigned initially to the one week group for short term evaluation of the device and to confirm the ease of use, and safety. Once each patient has completed 1 week of use without any complications, their physician may assign patients to either the four week group or the one week group (if the one week group, they will be done with the study) at their discretion. At the end of each week, subjects and their designated caregivers will be asked to return the EDAM to their clinic which will provide the device to the reading center based at the Retina Health Center. As in the clinical arm, all data will be removed and cleared from the EDAM devices by the reading center and stored on their secure servers for further assessment. EDAMs will then be returned to the clinic where they came from for use on other subjects. At this time, the subject and/or their designated caregiver will also be asked to complete another study questionnaire which will take 5-10 minutes (see appended questionnaire).

Since this is a pilot and exploratory study, it is desirable to allow flexibility to try and identify issues that may develop in both groups prior to undertaking a longer or larger study. Patients will be asked to use the drops routinely. The goal is to see if the EDAM is easy to use, if it captures the desired data, and to get an idea as to patient compliance in a random group of patients. As mentioned, at the end of each week, the patient (with their designated caregiver if applicable) will return to the clinic so a technician can download the accumulated videos and create a log documenting each drop procedure by noting whether each drop made it fully into the eye, half in, not in at all, or if they were unable to make an accurate assessment even with the video recording. This log will be viewed by the physician. The designated care giver may change between eye drop application procedures, but all care givers who assisted in the eye drop procedures must return with the subject to complete a study questionnaire.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who are scheduled to receive prescription eye drops

• Eye drop(s) must be applied at least once a day.

• Caregivers who apply drops for patients

Exclusion Criteria:

• Children (patients < 18 years old)

• Those unable to self-consent

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Any Condition That Requires Ophthalmic Drops
• Cataracts
• Glaucoma
• Retina Surgery

Locations

Country	Name	City	State
United States	Retina Health Center	Fort Myers	Florida

Sponsors (4)

Lead Sponsor	Collaborator
Alexander Eaton	California Retina Consultants, Konowal Vision Center, Southwest Florida Eye Care

Country where clinical trial is conducted

United States, 

References & Publications (1)

Eaton AM, Gordon GM, Konowal A, Allen A, Allen M, Sgarlata A, Gao G, Wafapoor H, Avery RL. A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study. Eye (Lond). 2015 Oct;29(10):1383-91. doi: 10.1038/eye.20 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variation from a Prescribed Ophthalmic Drop Regimen	The Eye Drop Application Monitor will be brought to the reading center based at Retina Health Center (Fort Myers, FL) at the end of each use. A trained technician will then document the time of drop delivery and how many drops got in the eye.	Up to four weeks of monitoring beginning immediately after eye drops are prescribed	No